



TO

All Providers, HMOs and Other Managed Care Programs

REGARDING

Reimbursement Rate Increase for COVID-19 Vaccine Administration

Reimbursement Rate Increase for COVID-19 Vaccine Administration

Effective for dates of service on and after April 1, 2021, ForwardHealth will increase the rate for COVID-19 vaccine administration to \$38.16, which aligns with the new Medicare reimbursement rate geographically adjusted for Wisconsin.

Reimbursement rates for a COVID-19 vaccine requiring a series of two or more doses will be the following:

- \$38.16 for administration of the initial dose(s)
- \$38.16 for administration of the final dose in the series

ForwardHealth will reimburse \$38.16 for the administration of a single dose COVID-19 vaccine.

Providers should include the following Current Procedural Terminology codes on claims for vaccine administration.

PROCEDURE CODE	DESCRIPTION
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, single dose

Resources

Additional information is available in the following ForwardHealth publications:

- Claim submission and reimbursement for COVID-19 vaccines: January 2021 ForwardHealth Update (2021-01), titled "[COVID-19 Vaccine Billing and Reimbursement](#)"
- SeniorCare COVID-19 vaccine coverage: February 2021 [Alert 031](#), titled "SeniorCare Covers the COVID-19 Vaccine Effective December 11, 2020"
- COVID-19-related diagnosis codes: February 2021 [Alert 033](#), titled "New COVID-19-Related Diagnosis Codes Available for Claims Submission"
- Clarifications of COVID-19 vaccine policy and coverage: March 2021 Update (2021-09), titled "[COVID-19 Vaccine Policy and Coverage Clarifications](#)"

COVID-19-related ForwardHealth Alerts and Updates are available on the [COVID-19: ForwardHealth News and Resources](#) page of the ForwardHealth Portal.